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Abstract 
Introduction: Many retrospective studies have confirmed that capecitabine combined with temozolomide is effective in neuroendocrine 
neoplasms. Most of the studies focused on grade 1 and grade 2 neuroendocrine tumours, mainly of pancreatic origin. There are limited 
data regarding the efficacy capecitabine with temozolomide in grade 3 neuroendocrine tumours. The new World Health Organisation 
2017 classification distinguished well-differentiated grade 3 neuroendocrine tumours from poorly differentiated grade 3 neuroendocrine 
carcinomas. Treatment options for grade 3 neuroendocrine neoplasms are limited, and the overall prognosis is better in the subgroup of 
patients with grade 3 neuroendocrine tumours. 
Material and methods: It was a retrospective study in the population of patients with diagnosed grade 3 neuroendocrine neoplasms of 
different origin treated with capecitabine and temozolomide. Data on clinical and demographic characteristics of the population were 
collected from four Polish clinical centres. This study aimed to evaluate response and survival parameters and compare outcomes of 
treatment of neuroendocrine tumours and carcinomas. 
Results: The study included 32 patients with grade 3 neuroendocrine tumours treated with capecitabine and temozolomide. The dis-
ease control rate was twice as high in the group of patient with neuroendocrine tumours in comparison to carcinomas (70 vs. 30%). The 
progression-free survival for patients with neuroendocrine tumours was 15.3 months (95% CI: 3.9–30.4), and for patients with neuroen-
docrine carcinomas it was 3.3 months (95% CI: 2.5–7.1). Median overall survival was 22 months (95% CI: 11.8–22.0) and 4.6 months (95% 
CI: 2.2–5.9) for patients with tumours and carcinomas, respectively.  The treatment regimen was generally well tolerated.
Conclusions: The combination of capecitabine and temozolomide is an effective treatment for patients with grade 3 neuroendocrine 
tumours with Ki-67 index ranging between 20 and 54%. The treatment did not overcome the aggressive character of neuroendocrine 
carcinomas and resulted in low response and survival outcomes in comparison to those achieved in tumour therapy. (Endokrynol Pol 
2019; 70 (4): 313–317)
Key words: capecitabine; grade 3 neuroendocrine neoplasms; neuroendocrine carcinoma; neuroendocrine tumour; temozolomide 
Endokrynologia Polska
DOI: 10.5603/EP.a2019.0010
Volume/Tom 70; Number/Numer 4/2019
ISSN 0423–104X
Introduction
The grading system for neuroendocrine tumours is 
based on the Ki-67 index and mitotic rate [1, 2]. A few 
per cent of all gastroenteropancreatic neuroendocrine 
neoplasms (NEN) have Ki-67 labelling index > 20% 
[3]. In the 2017 World Health Organisation classifica-
tion of neuroendocrine neoplasms they were divided 
into low-to-intermediate grade 1 (G1) and 2 (G2) NETs, 
and grade 3 (G3) neoplasms [1, 2]. In the high-grade 
category there are neoplasms with Ki-67 > 20% but 
containing well-differentiated and poorly-differen-
tiated neoplasms [4]. Poorly-differentiated G3 NEC 
has > 20 mitoses/10 high-power fields (HPF) and/or 
Ki-67 labelling index usually ≥ 55%. Well-differentiated 
G3 NET has Ki-67 usually between 20 and 54% [1, 2, 5]. 
This separation has clinical significance. G3 NETs and 
NECs differ considerably concerning their biological 
behaviour and patients’ outcome. The largest retrospec-
tive study on gastrointestinal NEN G3 — the so-called 
Nordic NEC trial — reported a lower response rate to 
platinum-based chemotherapy in patients with NETs 
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Statistical analysis
Descriptive statistical methods were used to summarise clinical 
characteristics. Progression-free survival (PFS) was defined as the 
time from the start of CAPTEM treatment to tumour progression or 
death. Overall survival (OS) was defined as the time from the start 
of CAPTEM treatment to death. Time-to-event data were analysed 
using Kaplan-Meier estimates. The log-rank test was used to com-
pare survival curves, and the effect of possible prognostic value of 
the Ki-67 index was calculated by Cox proportional hazards model. 
The data were analysed using MedCalc, version 18.11.3. 
Results
A total of 32 patients with G3 NENs and treated with 
CAPTEM were identified. All patients had started 
CAPTEM therapy during the last five years (between 
2013 and 2018), and follow-up ended at January 15th, 
2019. Patient characteristics are described in Table I. The 
mean (±SD) age was 55.0 (±15.8) years (range 27–78 
years). Thirty-one patients had non-functional tumours 
and one patient had a secreting tumour (insulinoma 
pancreatic NET). The median Ki-67 index was 52% 
(range 20–95%). Twenty patients were diagnosed with 
well-differentiated G3 NETs, with Ki-67 ranging from 
20 to 54. Twelve patients had neoplasms with Ki-67 
proliferation index ≥ 55% and diagnosis of G3 NEC. 
CAPTEM was used in the first-line in almost every third 
patient and in half of the patients in the second-line. 
The maximal number of previous lines of therapy be-
fore CAPTEM was four. The most common previous 
treatment was etoposide and cisplatin chemotherapy. 
compared to patients with high proliferative activity 
exceeding Ki-67 55% (15% vs. 42%; p < 0.01). Overall 
prognosis was superior in the subgroup of patients with 
Ki-67 < 55% [5]. Prognosis of patients with G3 NETs is 
worse in comparison to patients with a lower grade 
NET, but favourable compared to NECs. 
Treatment options for G3 NENs are limited. Retro-
spective data suggest that commonly applied first-line 
chemotherapy protocols including cisplatin or carbo-
platin in combination with etoposide are less effective 
in G3 NET than in G3 NEC. According to the ENETS 
guidelines, therapeutic alternatives comprise temozolo-
mide-based chemotherapy and peptide receptor radio-
nucleotide therapy in somatostatin receptor-positive 
tumours [6]. Specific trials for G3 NENs are necessary, 
and new therapies are urgently needed [7]. 
Combination of capecitabine and temozolomide 
(CAPTEM) is one of the systemic treatments used main-
ly in G1 and G2 pancreatic NETs, and to a lesser extent 
in gastroenetropatic NETs [8, 9]. There is no evidence 
from a randomised clinical trial on CAPTEM efficacy 
and safety. Data regarding the use of CAPTEM in G3 
NENs is minimal, and neoplasms with Ki-67 > 20% 
into NETs and NECs were not differentiated in the lit-
erature reporting the use of CAPTEM [9–12]. Recently 
sunitinib was shown to be as effective for G3 NETs as 
for G1/2 NETs [13].
Here, we present a retrospective analysis of clinical 
experience in patients with advanced stage G3 NENs, 
who were treated with CAPTEM.
Material and methods
Patient characteristics
Data of patients with G3 neuroendocrine neoplasms with Ki-67 
proliferating index > 20 and treated with at least one cycle of 
CAPTEM chemotherapy were collected from four Polish clinical 
centres from Katowice, Olsztyn, Szczecin, and Warsaw. There were 
no exclusion criteria to reflect the real-life practice of treatment of G3 
NENs. Records submitted by treating physicians were checked and 
reviewed for eventual discrepancies and to obtain supplementary 
information. Background characteristics investigated included age, 
gender, tumour origin, grade, hormonal activity, and type of previ-
ous and concomitant treatment. Start and stop dates of CAPTEM 
treatment, type and severity of toxicities, response to treatment, 
date of progression, and date of death were recorded. Adverse 
events were graded according to the Common Toxicity Criteria of 
Adverse Events (CTCAE) version 4.0 [14].
Patients received capecitabine at 600 mg/m2 orally twice daily on 
days 1–14 (maximum 1000 mg orally twice daily) and temozolomide 
150–200 mg/m2 once daily or divided into two doses daily, on days 
10–14 of a 28-day cycle. Dose modifications and dosing intervals 
were at the discretion of the treating physician.
Tumour response was routinely evaluated according to the response 
evaluation criteria in solid tumours (RECIST) [15]. Based on the Ki-
67 proliferative index tumours were divided according to the WHO 
2017 Classification [1] to compare survival outcomes of CAPTEM 
treatment. The observation period for each patient started with 
initiation of CAPTEM treatment. The follow-up period for this 
analysis ended on January 15th 2019. 
Table I. Baseline characteristics and demographics of patients
Characteristic Population (n = 32)
Age, mean ± SD, range, years 55.0 ± 15.8, 27–78
Male gender, n (%) 15 (46.9)
Origin of tumours, n (%)
Appendix 1 (3.1)
Colon 5 (15.6)
Gastric 5 (15.6)
Pancreas 13 (40,6)
Rectum 1 (3.1)
Retroperitoneal 2 (6.2)
Small bowel 5 (15.6)
Tumour functionality, n (%)
Non-functioning 31 (96.9)
Insulinoma 1 (3.1)
Ki-67 index, mean ± SD, range, % 52 ± 25.9, 20–95
Tumour grade*, n (%)
G3 NET (Ki-67 < 55%), n (%) 20 (62.5)
G3 NEC (Ki-67 ≥ 55%), n (%) 12 (37.5)
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CAPTEM was used in combination with a somatostatin 
analogue in nine patients. 
The median (±SD) time duration of treatment was 
5.4 months (range 1.0–30.4) months. Table II summarises 
the best response to treatment. The disease control rate 
was twice as high in the group of patients with NETs 
than in the G3 NEC group. 
Median PFS for all patients was 7.1 months (95% CI: 
3.27–15.3). Median PFS was significantly higher in the 
G3 NET group (15.3 months, 95% CI: 3.9–30.4) than in 
the G3 NEC group (3.3 months, 95% CI: 2.5–7.1) (hazard 
ratio 5.5, 95% CI: 2.0–15.0, p = 0.0009) (Fig. 1). 
Seventeen (53.1%) patients died. Median OS was 
15.6 months (95% CI: 8–22). Patients with NET-G3 had 
better overall survival (22 months; 95% CI: 11.8–22.0) 
than patients with NEC-G3 (4.6 months; 95% CI: 
2.2–5.9) (Fig. 1). The difference was statistically sig-
nificant (hazard ratio 4.0 95% CI: 1.2–13.0, p = 0.0178). 
The CAPTEM regimen was generally well tolerated. 
Grade 3 and 4 toxicities included thrombocytopaenia 
in five patients, neutropaenia in three patients, diar-
rhoea and hand-foot syndrome in two patients each, 
and fatigue in one patient. The most common grade 
1 and 2 toxicities were thrombocytopaenia, fatigue, 
neutropaenia, diarrhoea, and hand-foot syndrome. 
There were no opportunistic infections or adverse 
event-related deaths. There were two hospitalisations 
Table II. Response to treatment
Response to treatment All patients  
(n = 32)
G3 NET (Ki-67 < 55%)  
(n = 20)
G3 NEC (Ki-67 ≥ 55%) 
(n = 12)
Progressive disease, n (%) 14 (43.8%) 6 (30.0%) 8 (66.7%)
Stable disease, n (%) 7 (21.9%) 4 (20.0%) 3 (25.0%)
Partial response, n (%) 11 (34.4%) 10 (50.0%) 1 (8.3%)
Disease control rate (%) 56% 70% 33%
Table I. Baseline characteristics and demographics of patients
Characteristic Population (n = 32)
Treatment line, n (%)
1st line 10 (31.3)
2nd line 16 (50.0)
≥ 3rd line 8 (25.0)
CAPTEM + SSA 9 (28.1)
Previous treatment, n (%)
ETO + PLA 14 (43.8)
ETO + PLA + SSA 3 (9.3)
CAV 2 (6.2)
PRRT 2 (6.2)
PLA-Vinorelbine 1 (3.1)
DOXO+ DDP 1 (3.1)
DTIC+FFU 1 (3.1)
PRRT 2 (6.2)
Radiotherapy 2 (6.2)
Streptozotocin 2 (6.2)
Streptozotocin + 5FU 2 (6.2)
Sunitinib 1 (3.1)
CAV — cyclophosphamide, doxorubicin, vincristine; ETO + PLA — etoposide, 
cisplatin; DOXO — doxorubicin; DDP — diamine-dichloro-platinum;  
DTIC — dacarbazine; FFU — FOLFIRI- irinotecan, folinic acid, 5-fluorouracil; 
PRRT — peptide receptor radionuclide therapy; 5FU — 5-fluorouracil;  
SSA — somatostatin analogues; *According to 2017 WHO classification [1]
Figure 1. Survival outcomes of treatment with capecitabine and temozolomide: A. Progression-free survival. B. Overall survival 
in patients diagnosed with grade 3 neuroendocrine tumours (G3 NETs) and carcinomas (G3 NECs)
A B
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due to haematological toxicities, which fully recovered. 
Treating physicians  seven times decided to decrease 
dose or  delay next treatment cycle due to adverse 
events. All reported adverse events are summarised 
in Table III.
Discussion
Treatment for G3 NETs and NECs is not standardised. 
The first study to focus on the treatment of G3 NETs 
was conducted in 1991. The aim of the study was to 
access the effectiveness of cisplatin and etoposide in 
patients with G3 NETs. The results achieved in small 
cell lung cancer treatment inspired authors to evaluate 
that regimen in NECs [16]. The study for the first time 
showed that poorly-differentiated NECs show a better 
response (ORR = 67%) than well-differentiated NETs 
(ORR = 7%) to platinum-based chemotherapy. The 
toxicity of the treatment regimen was not acceptable. 
Thus, subsequent studies aimed to control the toxic-
ity by reducing the dose of etoposide, shortening the 
infusion time of cisplatin, and identifying predictors 
of high toxicity [17, 18]. Attempts to add paclitaxel to 
carboplatin and etoposide were unsuccessful [19]. In 
G3 NECs platinum-based chemotherapy is recom-
mended as the first-line therapy [20, 21]. The NORDIC 
NEC retrospective analysis published in 2012 showed 
that G3 neoplasms represent a heterogeneous group, 
because patients with well-differentiated tumours 
and lower Ki-67 (20–55%) show a poorer response 
to platinum-based chemotherapy than patients with 
Ki-67 > 55% [5]. As a result, the WHO G3 category was 
subdivided into two subtypes: G3 NET (Ki-67 20–55%) 
and G3 NEC (Ki-67 >55%) [1,2]. The biological behav-
iour of tumours with a Ki-67 index between 20 and 
55% is less aggressive than that of tumours with a Ki-67 
index above 55%, thus response to the same treatment 
is expected to be different. The distinction between G3 
NETs and G3 NECs is extremely important in determin-
ing treatment options for patients with G3 NENs.
The first randomised study reporting efficacy 
of cytotoxic therapy in NETs was by Moertel et al. 
[22]. It showed that streptozotocin-based therapies 
prolonged the survival time. Most of the other stud-
ies were studies without a control group; however, 
they resulted in widespread use of different alkylat-
ing agents and their combinations in the treatment 
of NETs [23]. Among them, a temozolomide-based 
regimen has emerged as a promising, well-tolerated, 
oral treatment. We are lacking an adequate prospec-
tive controlled study defining the role of temozolo-
mide in the treatment of NETs. The first controlled 
study to evaluate the usefulness of CAPTEM was the 
study by the ECOG-ACRIN Cancer Research Group. 
It showed that median PFS was 22.7 months for 
CAPTEM vs. 14.4 months for TEM in patients with 
low- or intermediate-grade advanced pancreatic NETs 
[25]. There are many retrospective and single-arm 
reports about CAPTEM use mainly in G1/G2 NETs 
of the pancreas [8, 9, 26, 27], but data on G3 NENs is 
very limited. The confirmed efficacy of the CAPTEM 
regimen in G1/2 NETs encouraged attempts to treat 
G3 NETs in the second-line therapy [5] and in patients 
with Ki-67 >20% [9–12]. In the literature we found 
descriptions of outcomes of CAPTEM therapy in 18 
patients with Ki-67 > 20% [9–12], and the treatment 
of NECs remains the domain of case reports [28].  
Here we present a cohort of 32 patients with G3 
NENs treated with CAPTEM regimen. To our knowl-
edge, this is the first study documenting the efficacy and 
safety of the CAPTEM regimen in subgroups of patients 
with high Ki-67 index, divided into G3 NETs and NECs 
based on the WHO 2017 classification [1]. The median 
PFS for all patients of 7.1 months (95% CI: 3.27–15.3) 
was comparable to the range from 3.4 to 6.0 months 
reported in the recent metanalysis by Lu et al. [29]. 
However, comparison of survival and response based 
on the Ki-67 level cut-off at 55% showed that results of 
the treatment were better in G3 NETs than in NECs. It 
is in line with the recent results for sunitinib efficacy in 
the treatment of G3 NENs [30]. G3 NETs and NECs are 
considered as different entities [1]. NECs have an ag-
gressive nature and a poor prognosis in comparisons 
to G3 NETs [5, 30]. CAPTEM treatment did not show to 
overcome aggressive character of NECs. 
Our study has some significant limitations. Because 
G3 NENs are rare, the study population was small. In 
addition, as a retrospective study the nonrandomised 
patient population were constraints in the analysis. Ac-
cepting the limitations, our study presents unique data 
Table III. Treatment toxicity
Adverse event Number of patients with
Grade 1–2 Grade 3–4
Thrombocytopaenia 12 5
Neutropaenia 9 3
Fatigue 11 1
Hand-foot syndrome 8 2
Diarrhoea 8 2
Nausea 5 0
Mucositis 3 0
Anaemia 4 0
Infection 6 0
Neuropathy 3 0
Hyperglycaemia 3 0
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on the efficacy of CAPTEM in the treatment of G3 NENs, 
with their differentiation to NETs and NECs.   
Conclusions
CAPTEM is an effective treatment for patients with G3 
NETs. The treatment did not overcome the aggressive 
character of NECs and resulted in low response and 
survival outcomes in comparison to those achieved in 
tumour therapy.
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